Identifying Novel Type ZBGs and Nonhydroxamate HDAC Inhibitors Through a SVM Based Virtual Screening Approach

Histone deacetylase inhibitors (HDACi) have been successfully used for the treatment of cancers and other diseases. Search for novel type ZBGs and development of non‐hydroxamate HDACi has become a focus in current research. To complement this, it is desirable to explore a virtual screening (VS) tool capable of identifying different types of potential inhibitors from large compound libraries with high yields and low false‐hit rates similar to HTS. This work explored the use of support vector machines (SVM) combined with our newly developed putative non‐inhibitor generation method as such a tool. SVM trained by 702 pre‐2008 hydroxamate HDACi and 64334 putative non‐HDACi showed good yields and low false‐hit rates in cross‐validation test and independent test using 220 diverse types of HDACi reported since 2008. The SVM hit rates in scanning 13.56 M PubChem and 168K MDDR compounds are comparable to HTS rates. Further structural analysis of SVM virtual hits suggests its potential for identification of non‐hydroxamate HDACi. From this analysis, a series of novel ZBG and cap groups were proposed for HDACi design.

[1]  Takayoshi Suzuki,et al.  Rational design of non-hydroxamate histone deacetylase inhibitors. , 2006, Mini reviews in medicinal chemistry.

[2]  M Reza Ghadiri,et al.  Probing the bioactive conformation of an archetypal natural product HDAC inhibitor with conformationally homogeneous triazole-modified cyclic tetrapeptides. , 2009, Angewandte Chemie.

[3]  Meir Glick,et al.  Enrichment of High-Throughput Screening Data with Increasing Levels of Noise Using Support Vector Machines, Recursive Partitioning, and Laplacian-Modified Naive Bayesian Classifiers , 2006, J. Chem. Inf. Model..

[4]  Carsten Schultz,et al.  Editorial: Closing the Gap between Chemistry and Biology , 2005, Chembiochem : a European journal of chemical biology.

[5]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[6]  Bo Yang,et al.  Design, synthesis and AChE inhibitory activity of indanone and aurone derivatives. , 2009, European journal of medicinal chemistry.

[7]  Joanna Kargul,et al.  Epigenetics and human disease. , 2009, The international journal of biochemistry & cell biology.

[8]  Paul Watson,et al.  Virtual Screening Using Protein-Ligand Docking: Avoiding Artificial Enrichment , 2004, J. Chem. Inf. Model..

[9]  Hendrik Luesch,et al.  Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. , 2008, Journal of the American Chemical Society.

[10]  Jérôme Hert,et al.  New Methods for Ligand-Based Virtual Screening: Use of Data Fusion and Machine Learning to Enhance the Effectiveness of Similarity Searching , 2006, J. Chem. Inf. Model..

[11]  Subhash C. Basak,et al.  Fourth Indo-U.S. Workshop on Mathematical Chemistry, January 8-12, 2005, Pune, Maharashtra, India , 2006, J. Chem. Inf. Model..

[12]  Jürgen Bajorath,et al.  Towards Unified Compound Screening Strategies: A Critical Evaluation of Error Sources in Experimental and Virtual High‐Throughput Screening , 2006 .

[13]  Giuseppe Battaglia,et al.  Interaction between ephrins/Eph receptors and excitatory amino acid receptors: possible relevance in the regulation of synaptic plasticity and in the pathophysiology of neuronal degeneration , 2006, Journal of neurochemistry.

[14]  Channa K. Hattotuwagama,et al.  Quantitative Structure-Activity Relationships of Sweet Isovanillyl Derivatives , 2001 .

[15]  Alain Ajamian,et al.  Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[16]  György M Keseru,et al.  Hit discovery and hit-to-lead approaches. , 2006, Drug discovery today.

[17]  Silvio Massa,et al.  3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C2 and/or -C4 Substitutions on Biological Activity† , 2004 .

[18]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[19]  Takayoshi Suzuki,et al.  Non-hydroxamate histone deacetylase inhibitors. , 2005, Current medicinal chemistry.

[20]  Leming Shi,et al.  Quantitative structure-activity relationship study of histone deacetylase inhibitors. , 2004, Current medicinal chemistry. Anti-cancer agents.

[21]  Manfred Jung,et al.  Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. , 2002, Journal of medicinal chemistry.

[22]  Xianghua Lin,et al.  Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways , 2008, Journal of hematology & oncology.

[23]  K. Stamatopoulos,et al.  ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia , 2007, Leukemia.

[24]  Olof Johansson,et al.  The role of colloid formation in the photoinduced H2 production with a Ru(II)-Pd(II) supramolecular complex: a study by GC, XPS, and TEM. , 2008, Journal of the American Chemical Society.

[25]  John M. Beierle,et al.  Characterization of Potent Histone Deacetylase Inhibitors Based on Cyclic r /-Tetrapeptide Architectures , 2009 .

[26]  Peter Claus,et al.  In vitro and ex vivo evaluation of second‐generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy , 2006, Journal of neurochemistry.

[27]  William J. Welsh,et al.  New Predictive Models for Blood–Brain Barrier Permeability of Drug-like Molecules , 2008, Pharmaceutical Research.

[28]  J. Denburg,et al.  Haemopoietic mechanisms in allergic rhinitis , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  Leandro Martínez,et al.  Molecular dynamics simulations of ligand dissociation from thyroid hormone receptors: evidence of the likeliest escape pathway and its implications for the design of novel ligands. , 2006, Journal of medicinal chemistry.

[30]  Edward N. Trifonov,et al.  Earliest pages of bioinformatics , 2000, Bioinform..

[31]  Christopher J. C. Burges,et al.  A Tutorial on Support Vector Machines for Pattern Recognition , 1998, Data Mining and Knowledge Discovery.

[32]  Z. R. Li,et al.  A support vector machines approach for virtual screening of active compounds of single and multiple mechanisms from large libraries at an improved hit-rate and enrichment factor. , 2008, Journal of molecular graphics & modelling.

[33]  Miguel A. Sierra.  Structure and Reactivity in Organic Chemistry. Edited by Mark G. Moloney. , 2009 .

[34]  Seth M. Cohen,et al.  Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity , 2006, JBIC Journal of Biological Inorganic Chemistry.

[35]  Alan J. M. Baker,et al.  Metal ion ligands in hyperaccumulating plants , 2005, JBIC Journal of Biological Inorganic Chemistry.

[36]  Bernard F. Buxton,et al.  Support Vector Machines in Combinatorial Chemistry , 2001 .

[37]  Hiroshi Chuman,et al.  Screening for New Antidepressant Leads of Multiple Activities by Support Vector Machines , 2006, J. Chem. Inf. Model..

[38]  S. Vadivelan,et al.  Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads. , 2008, Journal of molecular graphics & modelling.

[39]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[40]  Y. Z. Chen,et al.  In Silico Prediction of Pregnane X Receptor Activators by Machine Learning Approache , 2007, Molecular Pharmacology.

[41]  K. Glaser,et al.  Histone deacetylase inhibitors: the Abbott experience. , 2003, Current medicinal chemistry.

[42]  George Papadatos,et al.  Evaluation of machine-learning methods for ligand-based virtual screening , 2007, J. Comput. Aided Mol. Des..

[43]  Boon Chuan Low,et al.  Evaluation of Virtual Screening Performance of Support Vector Machines Trained by Sparsely Distributed Active Compounds , 2008, J. Chem. Inf. Model..

[44]  Evan W. Miller,et al.  A selective turn-on fluorescent sensor for imaging copper in living cells. , 2006, Journal of the American Chemical Society.

[45]  Jean-Louis Reymond,et al.  Virtual Exploration of the Chemical Universe up to 11 Atoms of C, N, O, F: Assembly of 26.4 Million Structures (110.9 Million Stereoisomers) and Analysis for New Ring Systems, Stereochemistry, Physicochemical Properties, Compound Classes, and Drug Discovery , 2007, J. Chem. Inf. Model..

[46]  Seth M Cohen,et al.  A new role for old ligands: discerning chelators for zinc metalloproteinases. , 2006, Journal of the American Chemical Society.

[47]  Silvio Massa,et al.  3-D QSAR Studies on Histone Deacetylase Inhibitors. A GOLPE/GRID Approach on Different Series of Compounds , 2006, J. Chem. Inf. Model..

[48]  V. Kulkarni,et al.  3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues. , 2006, Organic & biomolecular chemistry.

[49]  Zhihua Chen,et al.  Naphthalenedicarboximide- vs perylenedicarboximide-based copolymers. Synthesis and semiconducting properties in bottom-gate N-channel organic transistors. , 2009, Journal of the American Chemical Society.

[50]  H. Kwon,et al.  Trichostatin A attenuates airway inflammation in mouse asthma model , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[51]  Kathleen A. Durkin,et al.  Corrigendum to ''Bis-neonicotinoid insecticides: Observed and predicted binding interactions with the nicotinic receptor" (Bioorg. Med. Chem. Lett. 19 (2009) 3449) , 2009 .

[52]  B. Matthews.  Comparison of the predicted and observed secondary structure of T4 phage lysozyme. , 1975, Biochimica et biophysica acta.

[53]  J. An,et al.  Structure-based virtual screening of chemical libraries for drug discovery. , 2006, Current opinion in chemical biology.

[54]  Takahiro Ochi,et al.  Proinflammatory role of amphiregulin, an epidermal growth factor family member whose expression is augmented in rheumatoid arthritis patients , 2007, Journal of Inflammation.

[55]  A. Schuffenhauer,et al.  Charting biologically relevant chemical space: a structural classification of natural products (SCONP). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Daniel Delorme,et al.  Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation. , 2003, Current medicinal chemistry.

[57]  G. Giaccone,et al.  Histone deacetylase inhibitors in cancer therapy , 2008, Current opinion in oncology.

[58]  Hwangseo Park,et al.  Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitors , 2004, J. Comput. Aided Mol. Des..

[59]  Yan-shen Guo,et al.  Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses. , 2005, Bioorganic & medicinal chemistry.

[60]  Bernard F. Buxton,et al.  Drug Design by Machine Learning: Support Vector Machines for Pharmaceutical Data Analysis , 2001, Comput. Chem..

[61]  P. Jeffrey Conn.  Molecular Pharmacology in the Postgenomic Era , 2006 .

[62]  Milan Randic,et al.  "Anticonnectivity": A Challenge for Structure-Property-Activity Studies , 2006, J. Chem. Inf. Model..

[63]  Hans Briem,et al.  Classifying “Kinase Inhibitor‐Likeness” by Using Machine‐Learning Methods , 2005, Chembiochem : a European journal of chemical biology.

[64]  P. Tak,et al.  Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on? , 2008, Arthritis research & therapy.

[65]  Oliver Distler,et al.  Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[66]  Silvio Massa,et al.  Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies. , 2008, European journal of medicinal chemistry.

[67]  Michael K. Gilson,et al.  Virtual Screening of Molecular Databases Using a Support Vector Machine , 2005, J. Chem. Inf. Model..

[68]  Paola Gramatica,et al.  Principles of QSAR models validation: internal and external , 2007 .

[69]  Philip Jones,et al.  From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents. , 2008, Current pharmaceutical design.

[70]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[71]  Ill-Min Chung,et al.  Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. , 2007, Bioorganic & medicinal chemistry letters.

[72]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[73]  Alan M Rosenberg.  Pediatric rheumatology: where do we go from here? , 2006, The Journal of rheumatology.

[74]  J Andrew McCammon,et al.  Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor. , 2009, Journal of medicinal chemistry.

[75]  David W. Corne,et al.  Artificial Intelligence in Bioinformatics , 2001, Computers and Chemistry.

[76]  Masahiro Yamamura,et al.  Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. , 2004, Arthritis and rheumatism.

[77]  A. Kozikowski,et al.  Chemistry, Biology, and QSAR Studies of Substituted Biaryl Hydroxamates and Mercaptoacetamides as HDAC Inhibitors—Nanomolar‐Potency Inhibitors of Pancreatic Cancer Cell Growth , 2008, ChemMedChem.

[78]  Alfonso Lampen,et al.  Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. , 2006, Chemical research in toxicology.

[79]  Alain Ajamian,et al.  Sulfamides as novel histone deacetylase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.